This company has been acquired
FSTX Stock Overview
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
F-star Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.12 |
| 52 Week High | US$7.12 |
| 52 Week Low | US$2.07 |
| Beta | -0.35 |
| 1 Month Change | 47.72% |
| 3 Month Change | 26.47% |
| 1 Year Change | 138.13% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 75.37% |
Recent News & Updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15Recent updates
F-star Therapeutics: Running Into A National Security Roadblock
Sep 22F-star Therapeutics falls on extended CFIUS review for Sino-Biopharma sale
Sep 15F-star Therapeutics: A Merger Arbitrage Opportunity Expected To Close Soon
Jul 29F-star enters license deal with Takeda for a cancer immune therapy antibody
Jul 20Need To Know: Analysts Are Much More Bullish On F-star Therapeutics, Inc. (NASDAQ:FSTX) Revenues
May 18
US$26.50: That's What Analysts Think F-star Therapeutics, Inc. (NASDAQ:FSTX) Is Worth After Its Latest Results
Mar 17These Analysts Just Made An Incredible Downgrade To Their F-star Therapeutics, Inc. (NASDAQ:FSTX) EPS Forecasts
Mar 16F-star Therapeutics: Best-In-Class Tetravalent Bispecific Antibody Technology In Cancers
Jan 27F-star Therapeutics under pressure on pricing $65M stock offering
May 07Here's What F-star Therapeutics, Inc.'s (NASDAQ:FSTX) Shareholder Ownership Structure Looks Like
Mar 17Merck KGaA discloses 5.4% stake in F-star Therapeutics
Feb 02Dosing underway in early-stage study of F-star's FS120 in cancer
Dec 03Shareholder Returns
| FSTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 29.5% | -2.5% | -3.2% |
| 1Y | 138.1% | -3.7% | 19.3% |
Return vs Industry: FSTX exceeded the US Biotechs industry which returned 2.8% over the past year.
Return vs Market: FSTX exceeded the US Market which returned -9.9% over the past year.
Price Volatility
| FSTX volatility | |
|---|---|
| FSTX Average Weekly Movement | 27.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FSTX's share price has been volatile over the past 3 months.
Volatility Over Time: FSTX's weekly volatility has increased from 18% to 27% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 86 | Eliot Forster | www.f-star.com |
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company’s principal product candidate is FS118 and is being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients.
F-star Therapeutics, Inc. Fundamentals Summary
| FSTX fundamental statistics | |
|---|---|
| Market cap | US$156.51m |
| Earnings (TTM) | -US$44.75m |
| Revenue (TTM) | US$21.18m |
7.4x
P/S Ratio-3.5x
P/E RatioIs FSTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FSTX income statement (TTM) | |
|---|---|
| Revenue | US$21.18m |
| Cost of Revenue | US$0 |
| Gross Profit | US$21.18m |
| Other Expenses | US$65.92m |
| Earnings | -US$44.75m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | 100.00% |
| Net Profit Margin | -211.32% |
| Debt/Equity Ratio | 17.3% |
How did FSTX perform over the long term?
See historical performance and comparison